Evidence map›Paper›PMID 29995582›Full record

ArticleCell cycle (Georgetown, Tex.)2018

Regulation of cyclin E1 expression in human pluripotent stem cells and derived neural progeny.

María Soledad Rodríguez Varela, Sofía Mucci, Guillermo Agustín Videla Richardson, Olivia Morris Hanon, Verónica Alejandra Furmento, Santiago Gabriel Miriuka, Gustavo Emilio Sevlever, María Elida Scassa, Leonardo Romorini

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

María Soledad Rodríguez Varelaa Laboratorios de Investigación Aplicada en Neurociencias (LIAN-CONICET) , Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) , Belén de Escobar , Provincia de Buenos Aires , Argentina.
Sofía Muccia Laboratorios de Investigación Aplicada en Neurociencias (LIAN-CONICET) , Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) , Belén de Escobar , Provincia de Buenos Aires , Argentina.
Guillermo Agustín Videla Richardsona Laboratorios de Investigación Aplicada en Neurociencias (LIAN-CONICET) , Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) , Belén de Escobar , Provincia de Buenos Aires , Argentina.
Olivia Morris Hanona Laboratorios de Investigación Aplicada en Neurociencias (LIAN-CONICET) , Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) , Belén de Escobar , Provincia de Buenos Aires , Argentina.
Verónica Alejandra Furmentoa Laboratorios de Investigación Aplicada en Neurociencias (LIAN-CONICET) , Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) , Belén de Escobar , Provincia de Buenos Aires , Argentina.
Santiago Gabriel Miriukaa Laboratorios de Investigación Aplicada en Neurociencias (LIAN-CONICET) , Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) , Belén de Escobar , Provincia de Buenos Aires , Argentina.
Gustavo Emilio Sevlevera Laboratorios de Investigación Aplicada en Neurociencias (LIAN-CONICET) , Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) , Belén de Escobar , Provincia de Buenos Aires , Argentina.ORCID 0000-0002-9567-7553
María Elida Scassaa Laboratorios de Investigación Aplicada en Neurociencias (LIAN-CONICET) , Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) , Belén de Escobar , Provincia de Buenos Aires , Argentina.
Leonardo Romorinia Laboratorios de Investigación Aplicada en Neurociencias (LIAN-CONICET) , Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) , Belén de Escobar , Provincia de Buenos Aires , Argentina.
Consejo Nacional de Investigaciones Científicas y Técnicas · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human pluripotent stem cells (hPSCs), including embryonic and induced pluripotent stem cells (hESCs and hiPSCs) show unique cell cycle characteristics, such as a short doubling time due to an abbreviated G1 phase. Whether or not the core cell cycle machinery directly regulates the stemness and/or the differentiation potential of hPSCs remains to be determined. To date, several scenarios describing the atypical cell cycle of hPSCs have been suggested, and therefore there is still controversy over how cyclins, master regulators of the cell cycle, are expressed and regulated. Furthermore, the cell cycle profile and the expression pattern of major cyclins in hESCs-derived neuroprogenitors (NP) have not been studied yet. Therefore, herein we characterized the expression pattern of major cyclins in hPSCs and NP. We determined that all studied cyclins mRNA expression levels fluctuate along cell cycle. Particularly, after a thorough analysis of synchronized cell populations, we observed that cyclin E1 mRNA levels increased sharply in G1/S concomitantly with cyclin E1 protein accumulation in hPSCs and NP. Additionally, we demonstrated that cyclin E1 mRNA expression levels involves the activation of MEK/ERK pathway and the transcription factors c-Myc and E2Fs in hPSCs. Lastly, our results reveal that proteasome mediates the marked down-regulation (degradation) of cyclin E1 protein observed in G2/M by a mechanism that requires a functional CDK2 but not GSK3β activity. ABBREVIATIONS: hPSCs: human pluripotent stem cells; hESCs: human embryonic stem cells; hiPSCs: human induced pluripotent stem cells; NP: neuroprogenitors; HF: human foreskin fibroblasts; MEFs: mouse embryonic fibroblasts; iMEFs: irradiated mouse embryonic fibroblasts; CDKs: cyclindependent kinases; CKIs: CDK inhibitors; CNS: central nervous system; Oct-4: Octamer-4; EB: embryoid body; AFP: Alpha-fetoprotein; cTnT: Cardiac Troponin T; MAP-2: microtubule-associated protein; TUJ-1: neuron-specific class III β-tubulin; bFGF: basic fibroblastic growth factor; PI3K: Phosphoinositide 3-kinase; KSR: knock out serum replacement; CM: iMEF conditioned medium; E8: Essential E8 medium.

Indexed as

Gene Expression RegulationCell ProliferationCells, CulturedCyclin EE2F Transcription FactorsExtracellular Signal-Regulated MAP KinasesFibroblastsG1 Phase Cell Cycle CheckpointsG2 PhaseHumansMitogen-Activated Protein Kinase KinasesMitosisNeural Stem CellsNeuronsOncogene ProteinsPluripotent Stem CellsCCNE1 protein, humanCyclin EE2F Transcription FactorsExtracellular Signal-Regulated MAP KinasesMitogen-Activated Protein Kinase KinasesOncogene ProteinsProto-Oncogene Proteins c-mycRNA, MessengerCDK2cell cycleCyclin E1cyclinshESCshiPSCshuman embryonic stem cellshuman induced pluripotent stem cellsneuroprogenitorsstem cells

Identifiers

PMID29995582
PMCPMC6133309
OpenAlexW2812150128

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.